The need for a better identification of COPD-bronchiectasis phenotype

A. de Sousa Fernandes (Oliveira de Azeméis, Portugal)

Source: International Congress 2017 – Management of COPD
Session: Management of COPD
Session type: Poster Discussion
Number: 3249
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. de Sousa Fernandes (Oliveira de Azeméis, Portugal). The need for a better identification of COPD-bronchiectasis phenotype. 3249

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A new score to identify patients who need fitness to fly test
Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions
Year: 2018

What do we need in the clinic and what approach can clinicians take to improve the drug development pipeline?
Source: ERS Research Seminar 2016
Year: 2016

COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging
Source: Eur Respir J, 52 (5) 1801570; 10.1183/13993003.01570-2018
Year: 2018



Population segmentation to identify priority targets for identification and behaviour change interventions in COPD
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011


A simple algorithm for the identification of clinical COPD phenotypes
Source: Eur Respir J, 50 (5) 1701034; 10.1183/13993003.01034-2017
Year: 2017



Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

The role of gene–environment interactions in lung disease: the urgent need for the exposome
Source: Eur Respir J, 55 (2) 1902064; 10.1183/13993003.02064-2019
Year: 2020



What regulatory framework is preferable for successful harm reduction?
Source: Research Seminar 2005 - Tobacco Smoking: Harm Reduction Strategies
Year: 2005

Genetic studies as a tool for identifying novel potential targets for treatment of COPD
Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Year: 2017



The impact of a new recruitment strategy to improve recruitment of participants to research studies
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019


Can lung function tests help identify functional phenotypes in children with asthma?
Source: Virtual Congress 2021 – Respiratory physiology and breathing during sleep in health and sickness
Year: 2021

Physicians or prediction rules; who is better at predicting prognosis?
Source: Eur Respir J 2007; 30: Suppl. 51, 124s
Year: 2007

How can we achieve better prevention of progression to tuberculosis among contacts?
Source: Eur Respir J 2013; 42: 1743-1746
Year: 2013


The need and potential of patient-specific modelling
Source: Annual Congress 2012 - PG13 AirPROM: patient-specific modelling and systems biology living labs workshop
Year: 2012



TB education - a method for better therapeutic results
Source: Eur Respir J 2002; 20: Suppl. 38, 548s
Year: 2002

Using population insight studies to define effective prevention and identification interventions in COPD
Source: Annual Congress 2011 - Quality of diagnosis and assessment in primary care
Year: 2011


The goal is to go further and do better: but how?
Source: Eur Respir Rev 2015; 25: 1-3
Year: 2016